The co-silencing phenomenon of cancer genes in the malignant evolution of tumor.

To deal with malignant tumors, nucleic acid drugs have received more and more attention in recent years because of good targeting and therapeutic effect.
scientists are still trying to find new targeted drugs and research directions that awaken the body's own immune function when dealing with tumors, so that cancer-suppressing genes no longer act as "silent lambs." Professor Yang Cheng of Nankai University School of Pharmacy,
, studied the phenomenon of co-silencing cancer genes in the malignant evolution of tumors, and designed artificial single-stranded ring DNA carried by nano-microspheres to improve the expression level of cancer-suppressing genes by adsorption of miRNA, thereby suppressing tumor progression.
's research by Professor Yang Cheng's team was reported in an August cover article in Cancer Research, an internationally renowned academic journal published by the American Cancer Society.
breaking the "co-silence" helps to suppress the phenomenon of low expression of cancer-suppressing genes in tumor cells in cancer tumor patients, and a variety of cancer-suppressing gene co-silencing silencing leads to an increase in tumor malignancy.
traditional anti-tumor drugs mostly target individual cancer genes rather than anti-cancer genes, especially few anti-tumor drugs that can simultaneously target multiple cancer-suppressing genes.
therefore, "if the anti-cancer genes can be activated, and they are fully motivated, dealing with tumors may be another scenario."
," Yang said.
what is gene co-silence? Yang Explained that gene silencing refers to the fact that genes present in organisms are not lost or damaged, but the gene is not expressed or expressed very low.
", like humans, multiple genes do not 'talk', that is, gene co-silencing phenomenon, such silence in the fight against tumors is very terrible.
," Yang said in an image.
gene silencing is an important means of gene expression regulation of eukaryotic cell, and it is also a hot topic in biomedical research.
previous studies have found that klF17, CDH1 and LASS2 are low-expression of klF17, CDH1 and LASS2 in a variety of tumors, and the co-silence of cancer-suppressing genes is strongly correlated with the short life span of tumor patients.
now studies have confirmed that abnormal regulation of miRNA is also strongly associated with malignant tumors, and many miRNAs can often be regulated against multiple target genes.
Yang Cheng stressed that regulating the level of miRNA in the cell may simultaneously release the anti-cancer gene, breaking its co-silence, the future may become a more effective cancer treatment.
study found that miRNA-9 in tumors inhibited the expression of three cancer-suppressing genes KLF17, CDH1 and LASS2.
, scientists are working on an experiment to reduce the level of miRNA-9 in cancer cells, thereby lifting the co-silence of cancer-suppressing genes, improving the level of expression of inhibitors in patients, and effectively fighting tumors.
new ring DNA into a "absorbent" sponge Yang Cheng, in their study, they designed a special single-stranded ring DNA (CSSD), ring-like DNA is a class of common-valent closed DNA.
the ring DNA is designed to simulate the ring RNA (circRNA) present in the body, which is highly conservative and more stable than linear RNA.
" recent research has found that some circRNAs contain miRNA binding sites that can be used as miRNA 'sponge' adsorption miRNAs.
we simulate circRNA properties by designing ring-like DNA rich in miRNA binding sites to further improve its stability in the human body, allowing it to adsorption miRNA-9 and inhibit its function.
" Yang cheng said, their team designed a variety of CSSDs, one of which contains continuous multiple miRNA-9 adsorption sites of artificial ring-shaped single-stranded DNA (CSSD-9), with better stability and resistance to degradation.
experimental results also validate the original idea.
results show that CSSD can effectively inhibit tumor progression and metastasis by adsorbling the cancer-causing miRNA-9 and releasing cancer-suppressing genes - KLF17, CDH1 and LASS2, breaking the common "silence" phenomenon of the "three brothers" before, which increases the vitality and expression of these anti-cancer genes within cancer cells.
results show that in liver cancer, breast cancer, lung cancer, ovarian cancer, cervical cancer and other high miRNA-9 content of tumors, this new type of cyclic DNA drug has obvious adsorption effect, can fully mobilize the enthusiasm and initiative of cancer control genes.
the prospect of the new target drug is widely found in in vitro experiments, they developed and designed artificial single-stranded ring DNA for normal cells and mouse organs have no obvious toxic effect, and the mice have a certain increase in immunity.
therefore, the study proposes a new and stable and effective miRNA inhibitor, CSSD, to release a series of "co-silent" anticancer genes.
"From the perspective of adsorption miRNA release of co-silent anti-cancer genes, our study may provide a multi-target potential anti-tumor drug for tumor treatment."
" Yang Cheng said with a little excitement: "Although the road ahead is still long, but finally took the first step."
" Yang Cheng's research and development direction is mainly aimed at the molecular mechanism of epigenetic control of malignant tumor metastasis and the development of non-coding nucleic acid drugs.
, the first international report of the Polycycline "old drug new use" anti-tumor target PAR1, is Yang Cheng's team's research results.
now, the study is now in Phase I-II clinical trials as a new type of targeted drug.
" road to Rome, each target value of 10,000 gold.
"In the field of bio-targeted drug research and development, there has always been a saying that every drug research and development target may be a billion dollars of heavy products, may end up investing a huge amount of money, very little.
This time, Yang Cheng and his team have undoubtedly opened a new door to the fight against cancer.
.